Health · Medical Research · 49 mins ago
AR1001 slows decline in some people with early Alzheimer’s in trial
A phase III trial tested the daily pill AR1001 in 1,535 people with Alzheimer’s at 230 sites in 13 countries, including the United Kingdom.
The drug, also called mirodenafil, is made by South Korean firm AriBio and belongs to the same drug class as sildenafil, used in Viagra.
Participants taking AR1001 alone showed 31 per cent less decline in memory, thinking and everyday activities than those given a placebo over one year, equivalent to a delay of about 3.5 months.
Results were mixed for people taking other dementia medicines: the reported benefit was 7 per cent and was not statistically significant.
Most side effects were mild or moderate; diarrhoea, falls and dizziness were among the most common.
The findings suggest the tablet may slow decline, but further investigation is needed, particularly for people taking other dementia drugs.
AR1001 showed mixed results in a phase III trial involving people with early Alzheimer’s disease.
Among participants not taking other dementia medicines, those given AR1001 performed 31 per cent better than the placebo group on an assessment of memory, thinking and everyday functioning.
The reported benefit was not statistically significant among participants taking AR1001 alongside other dementia drugs.
The global trial involved 1,535 people at 230 sites in 13 countries, including the United Kingdom.
Most reported side effects were mild or moderate, with diarrhoea, falls and dizziness among the most common.
- Who
- The trial involved 1,535 people with Alzheimer’s disease. AriBio, a South Korean pharmaceutical firm, makes AR1001.
- What
- The phase III trial found a benefit on an assessment of memory, thinking and everyday functioning in participants not taking other dementia medicines. The result was not statistically significant for those taking other dementia drugs.
- When
- Results were presented on 16 November 2026, according to the article published that day.
- Where
- The trial ran at 230 sites in 13 countries, including the United Kingdom. The results were presented at a conference in Boston, United States.
- Why
- The trial tested AR1001 as a treatment for early Alzheimer’s disease. The articles do not state the trial’s specific reason for testing the drug.
This story does not have two clearly opposing sides.
Researchers assessed participants’ memory, thinking and everyday functioning.
Results were presented at the Clinical Trials on Alzheimer's Disease conference in Boston, United States.
- Drug
- AR1001, also known as mirodenafil
- Trial
- Phase III POLARIS-AD
- Participants
- 1,535 people with Alzheimer’s disease
- Trial sites
- 230 sites in 13 countries, including the United Kingdom
- Monotherapy result
- 31 per cent better than placebo on an assessment of memory, thinking and everyday functioning
- Concurrent dementia drugs
- 7 per cent benefit, not considered statistically significant
3 sources
What people are saying
These topline results are an encouraging sign that we could have a new treatment for early Alzheimer's disease that tackles its causes, not just its symptoms.
However, results were not apparent in people taking other drugs for Alzheimer's symptoms, so this needs further investigation.